||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors

F. Hoffmann-La Roche Ltd /
Roche's Hemlibra provided sustained bleed control in the largest pivotal study
to date of children with haemophilia A with factor VIII inhibitors
. Processed and transmitted by West Corporation.
The issuer is solely responsible for the content of this announcement.

* Nearly 77% of children receiving Hemlibra once weekly experienced zero
treated bleeds
* Hemlibra once weekly reduced treated bleeds by 99% compared to prior
bypassing agents in a prospective intra-patient comparison
* Hemlibra every two weeks and every four weeks also showed clinically
meaningful control of bleeding

Basel, 3 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data
from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra®
(emicizumab) prophylaxis in children younger than 12 years of age with
haemophilia A with factor VIII inhibitors, including longer follow-up for once-
weekly dosing and new data for less frequent dosing schedules (every two weeks
or every four weeks). These data from the largest pivotal study in children with
haemophilia A with factor VIII inhibitors were presented at the 60th American
Society of Hematology (ASH) Annual Meeting.

"Children with inhibitors are at increased risk of life-threatening bleeds and
may experience frequent, repeated bleeding into joints," said Guy Young, MD,
Director of Hemostasis and Thrombosis Center, Children's Hospital Los Angeles,
and Professor of Pediatrics, University of Southern California Keck School of
Medicine, Los Angeles, California. "These updated data from HAVEN 2 showed that
the majority of children with haemophilia A with factor VIII inhibitors treated
with emicizumab had zero treated bleeds across three different dosing schedules,
reinforcing the ability of this medicine to provide sustained, effective bleed
control."

In updated results from the HAVEN 2 study with a median of 11 additional months
of data, 76.9% (95% CI: 64.8; 86.5) of children with haemophilia A with factor
VIII inhibitors treated with Hemlibra once weekly (n=65) experienced zero
treated bleeds. Importantly, once-weekly Hemlibra showed a 99% (95% CI:
97.7; 99.4) reduction in treated bleeds compared to prior treatment with
bypassing agents (BPAs) as prophylaxis (n=15) or on-demand (n=3) in a
prospective intra-patient comparison. New data also showed that 90% (95% CI:
55.5; 99.7) of children with factor VIII inhibitors receiving Hemlibra every two
weeks (n=10) and 60% (95% CI: 26.2; 87.8) of children receiving Hemlibra every
four weeks (n=10) experienced zero treated bleeds, demonstrating clinically
meaningful bleed control at both dosing schedules. No cases of thrombotic
microangiopathy (TMA) or thrombotic events occurred. The most common adverse
events (AEs) in the HAVEN 2 study primary analysis were consistent with those
previously observed in the interim analyses.

"The updated analysis from the HAVEN 2 study supports the potential of Hemlibra
to control bleeds at less frequent subcutaneous dosing, providing parents and
their children more flexibility to choose a treatment schedule that is right for
them," said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global
Product Development. "Many children with haemophilia A with factor VIII
inhibitors have already experienced the benefits of Hemlibra, and with these new
positive data, we are confident that this treatment will continue to make a
meaningful difference in their lives."
Hemlibra is approved in over 50 countries worldwide, including the US, EU member
states and Japan, to treat people of all ages with haemophilia A with factor
VIII inhibitors based on pivotal data that included interim results from the
HAVEN 2 study. In October 2018, the FDA also approved Hemlibra to treat people
of all ages with haemophilia A without factor VIII inhibitors. Hemlibra is the
only FDA-approved treatment for people with haemophilia A with and without
factor VIII inhibitors that can be administered subcutaneously (under the skin)
and at multiple dosing options (once weekly, every two weeks or every four
weeks). The Marketing Authorisation Application variation for haemophilia A
without factor VIII inhibitors is currently under review by the European
Medicines Agency. Submissions to other regulatory authorities around the world
are ongoing.

Hemlibra has been studied in one of the largest pivotal clinical trial
programmes in people with haemophilia A with and without factor VIII inhibitors,
including four phase III HAVEN studies (HAVEN 1, HAVEN 2, HAVEN 3 and HAVEN 4).

About HAVEN 2 (NCT02795767)
HAVEN 2 is a multicentre, open-label, clinical study in children younger than
12 years of age with haemophilia A with factor VIII inhibitors. The study is
evaluating the efficacy, safety and pharmacokinetics of once-weekly, every two
weeks or every four weeks subcutaneous administration of Hemlibra prophylaxis.

The HAVEN 2 primary analysis included 85 children (once-weekly dosing, n=65;
every two week dosing, n=10; every four week dosing, n=10) with haemophilia A
with factor VIII inhibitors. The median follow-up period for each cohort was 58
(range 17.9-92.6), 21.3 (range 18.6-24.1), and 19.9 (range 8.9-24.1) weeks,
respectively. The prospective intra-patient comparison included 18 patients from
the once-weekly cohort previously treated with BPAs either as prophylaxis (n=15)
or on-demand (n=3) as part of a non-interventional study.

The study met its primary endpoint and key secondary endpoints. Data presented
at the 60th ASH Annual Meeting showed:

+------------------------------------------------------------------------------+
| HAVEN 2 (NCT02795767) |
+------------------------------------------------------------------------------+
| Hemlibra prophylaxis 1.5 mg/kg QW |
| (Arm A; n=65)* |
+--------------------------+------------------------+--------------------------+
|  |Annualised bleeding rate| Median ABR |
| | [ABR]( + |(Interquartile range; IQR)|
| | )(95% CI) | |
+--------------------------+------------------------+--------------------------+
|Treated bleeds (primary | 0.3 | 0.0 |
|endpoint)** | (0.17; 0.50) | (0.00; 0.00) |
+--------------------------+------------------------+--------------------------+
|All bleeds | 3.2 | 0.6 |
| | (1.94; 5.22) | (0.00; 2.92) |
+--------------------------+------------------------+--------------------------+
|Treated spontaneous bleeds| 0.0 | 0.0 |
| | (0.01; 0.10) | (0.00; 0.00) |
+--------------------------+------------------------+--------------------------+
|Treated joint bleeds | 0.2 | 0.0 |
| | (0.08; 0.29) | (0.00; 0.00) |
+--------------------------+------------------------+--------------------------+
|Treated target joint | Not estimable | 0.0 |
|bleeds | | (0.00; 0.00) |
+--------------------------+------------------------+--------------------------+
*Efficacy assessment was conducted only in patients aged <12 years who had spent
at least 12 weeks on the study. Excludes three patients aged >12 years.
A loading dose of 3 mg/kg Hemlibra was given for four weeks followed by the
maintenance dose listed.
(+) Estimated using negative binomial regression
**In patients receiving Hemlibra once weekly (Arm A), 76.9% (95% CI,
64.8; 86.5) experienced zero treated bleeds and 23.1% experienced 1-3 treated
bleeds.

+------------------------+--------------------------+--------------------------+
|  | Hemlibra prophylaxis 3 | Hemlibra prophylaxis 6 |
| | mg/kg Q2W | mg/kg Q4W |
| | (Arm B; n=10)* | (Arm C; n=10)* |
+------------------------+--------------------------+--------------------------+
| ABR (95% CI)( +) | 0.2 | 2.2 |
| | (0.03-1.72) | (0.69-6.81) |
+------------------------+--------------------------+--------------------------+
| Median ABR (IQR) | 0.0 | 0.0 |
| | (0.00-0.00) | (0.00-3.26) |
+------------------------+--------------------------+--------------------------+
| % patients with zero | 90.0% | 60.0% |
| treated bleeds | (55.5; 99.7) | (26.2; 87.8) |
| (95% CI) | | |
+------------------------+--------------------------+--------------------------+
| % patients with 1-3 | | |
| treated bleeds | 10.0% | 40.0% |
| (95% CI) | | |
+------------------------+--------------------------+--------------------------+
*A loading dose of 3 mg/kg Hemlibra was given for four weeks followed by the
maintenance dose listed.
+ Estimated using negative binomial regression


The most common adverse reactions occurring in 10% or more of children treated
with Hemlibra were common cold symptoms (nasopharyngitis; 37.5%), injection site
reactions (29.5%), fever (pyrexia; 23.9%), upper respiratory tract infection
(23.9%), cough (23.9%), diarrhoea (15.9%), vomiting (15.9%), headache (14.8%),
contusion (12.5%), fall (12.5%) and influenza (10.2%). No cases of TMA or
thrombotic events occurred. Four patients tested positive for anti-drug
antibodies (ADAs) to Hemlibra. Of these patients, two had ADAs with neutralising
potential based on reduced Hemlibra levels. As previously reported, the ADA in
one of these patients resulted in reduced efficacy of Hemlibra and led to
discontinuation of treatment. The other patient had no bleeds as of the clinical
cut-off date of the study.

About Hemlibra (emicizumab)
Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is
designed to bring together factor IXa and factor X, proteins required to
activate the natural coagulation cascade and restore the blood clotting process
for people with haemophilia A. Hemlibra is a prophylactic (preventative)
treatment that can be administered by an injection of a ready-to-use solution
under the skin (subcutaneously) once-weekly, every two weeks or every four
weeks. Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-
developed globally by Chugai, Roche and Genentech. It is marketed in the United
States by Genentech as Hemlibra (emicizumab-kxwh), with kxwh as the suffix
designated in accordance with Non-proprietary Naming of Biological Products
Guidance for Industry issued by the US Food and Drug Administration.

About haemophilia A
Haemophilia A is an inherited, serious disorder in which a person's blood does
not clot properly, leading to uncontrolled and often spontaneous bleeding.
Haemophilia A affects around 320,000 people worldwide, [1;2] approximately
50-60% of whom have a severe form of the disorder. [3] People with haemophilia A
either lack or do not have enough of a clotting protein called factor VIII. In a
healthy person, when a bleed occurs, factor VIII brings together the clotting
factors IXa and X, which is a critical step in the formation of a blood clot to
help stop bleeding. Depending on the severity of their disorder, people with
haemophilia A can bleed frequently, especially into their joints or muscles. [1]
These bleeds can present a significant health concern as they often cause pain
and can lead to chronic swelling, deformity, reduced mobility, and long-term
joint damage. [4] A serious complication of treatment is the development of
inhibitors to factor VIII replacement therapies. [5] Inhibitors are antibodies
developed by the body's immune system that bind to and block the efficacy of
replacement factor VIII, [6] making it difficult, if not impossible to obtain a
level of factor VIII sufficient to control bleeding.


What is haemophilia A?


About Roche in haematology
For more than 20 years, Roche has been developing medicines that redefine
treatment in haematology. Today, we are investing more than ever in our effort
to bring innovative treatment options to people with diseases of the blood. In
addition to approved medicines MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro®
(obinutuzumab), and Venclexta®/Venclyxto(TM) (venetoclax) in collaboration with
AbbVie, Roche's pipeline of investigational haematology medicines includes
Tecentriq® (atezolizumab), an anti-CD79b antibody drug conjugate (polatuzumab
vedotin/RG7596) and a small molecule antagonist of MDM2 (idasanutlin/RG7388).
Roche's dedication to developing novel molecules in haematology expands beyond
malignancy, with the development of Hemlibra® (emicizumab), a bispecific
monoclonal antibody for the treatment of haemophilia A.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people's lives. The combined strengths of
pharmaceuticals and diagnostics under one roof have made Roche the leader in
personalised healthcare - a strategy that aims to fit the right treatment to
each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology and
diseases of the central nervous system. Roche is also the world leader in in
vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in
diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose
and treat diseases and make a sustainable contribution to society. The company
also aims to improve patient access to medical innovations by working with all
relevant stakeholders. Thirty medicines developed by Roche are included in the
World Health Organization Model Lists of Essential Medicines, among them life-
saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth
consecutive year, Roche has been recognised as the most sustainable company in
the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100
countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche
invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more
information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.


References
[1] WFH. Guidelines for the management of haemophilia. 2012 [Internet; cited
2018 October]. Available from: http://www1.wfh.org/publications/files/pdf-
1472.pdf.
[2] Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet
2012; 370:1447-1456.
[3] Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical
Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and
Wilkin.
[4] Franchini M, Mannucci PM. Haemophilia A in the third millennium. Blood Rev
2013; 179-84.
[5] Gomez K, et al. Key issues in inhibitor management in patients with
haemophilia. Blood Transfus. 2014; 12:s319-s329.
[6] Whelan, SF, et al. Distinct characteristics of antibody responses against
factor VIII in healthy individuals and in different cohorts of haemophilia A
patients. Blood 2013; 121:1039-48.


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow

Haemophilia_A_infographic:
http://hugin.info/174806/R/2227161/874470.pdf

Roche-Media-Release-ASH_Hemlibra_HAVEN2_EN:
http://hugin.info/174806/R/2227161/874469.pdf



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: F. Hoffmann-La Roche Ltd via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.075 Sekunden